

P: 1300 688 522 E: info@nutripath.com.au

-.AMY PHILLIPS
AIM Natural Healthcare
Shop 1/132 WILLOUGHBY ROAD
CROWS NEST NSW 2065

## NICOLE PUSIC 13-Dec-1981

4 CENTENNIAL AVENUE LANE COVE NORTH NSW 2066

LAB ID: 3892069 UR NO.: 6191516

Collection Date: 15-May-2023 Received Date: 19-May-2023



3892069

**Female** 

## INTEGRATIVE MEDICINE

BLOOD - EDTA Result Range Units

## **HLA DQ/DR Haplotypes**

HLA DR/DQ Genotyping:

HLA-DR 3,15 DRB-1 03,15 HLA-DQ 2,6 HLA-DQA1 01,05 HLA-DQB1 02,06

Test performed by accredited laboratory NATA: 2133

## INTERPRETATION:

For CIRS/Moulds biotoxins exposure:

The following possible HLA-DR haplotypes were detected:

15-6-51 - Post Lyme/MS/Narcolepsy

17-2-52A/B/C - Mould Susceptible or Benign

## Post Lyme/MS/Narcolepsy 15-6-51

With regard to biotoxin susceptibility it is reported that this haplotype is statistically correlated with an increased incidence of chronic persistent lyme disease. Importantly, possessing this haplotype does not mean that you have lyme disease. Rather it means only that you may be at an increased risk of developing persistent lyme disease should you initially develop lyme disease by traditional means, such as being bitten by a tick. It has been said that the immune system of those with this haplotype may be unable or less able to properly identify and elimiate toxins associated with lyme disease, specifically those produced by bacteria of the Borrelia type.

Aspects of this haplotype have also been statistically correlated with an increased incidence of multiple sclerosis. Again, it is important to understand that possessing this haplotype does not mean that you have multiple sclerosis. Rather it means only that you may be at an increased risk of developing multiple sclerosis. In fact, research has suggested that this increased risk is related to low levels of vitamin D, and that it may be possible to offset the increased risk associated with this haplotype by always ensuring sufficiency.

Aspects of this haplotype have also been statistically correlated with an increased incidence of narcolepsy. This does not mean that you have narcolepsy. Rather it means only that you may be at an increased risk of developing narcolepsy.

## Disease Risk:

Some versions of this haplotype may confer additional risk of Multiple Sclerosis, Narcolepsy, Parkinson's Disease or Systemic Lupus Erythematosus.

Elements of this haplotype may confer additional susceptibility to Aspergillosis. Some versions of this haplotype may confer additional risk of Alzheimer's Disease.

## Disease Protection:

Some versions of this haplotype are reported to be protective against Type 1 Diabetes.

Haplotype: MOULD SUSCEPTIBLE 7-2-53, 7-3-53

13-6-52A, 13-6-52B, 13-6-52C 17-2-52A, 17-2-52B, 18-4-52A

With regard to biotoxin susceptibility it is reported that this haplotype is statistically correlated with an increased susceptibility to biotoxins from mould. Importantly, possessing this haplotype does not signify the presence of mould, mycotoxins or other related elements within the body nor is it an indication of past or present exposure. Rather it has been suggested that the immune system of those with this haplotype may be unable or less able to properly identify and eliminate toxins from mould.

Page 1 of 3 Final Report Printed:May 31, 2023



P: 1300 688 522 E: info@nutripath.com.au

-. AMY PHILLIPS **AIM Natural Healthcare** Shop 1/132 WILLOUGHBY ROAD **CROWS NEST NSW 2065** 

## **NICOLE PUSIC** 13-Dec-1981 **Female**

**4 CENTENNIAL AVENUE LANE COVE NORTH NSW 2066** 

LAB ID: 3892069 UR NO.: 6191516

Collection Date: 15-May-2023 Received Date: 19-May-2023



3892069

## Disease Risk:

This haplotype may confer additional risk of Celiac Disease, Sjorgen's Syndrome or Addison's Disease. Some versions of this haplotype may confer additional risk of Psoriasis, Type 1 Diabetes or Systemic Lupus

Some versions of this haplotype may confer additional risk of Grave's Disease Elements of this haplotype may confer additional risk of Multiple Sclerosis

## Disease Protection:

Elements of this haplotype are reported to be protective against Systemic Lupus Erythematosus, Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis or Alopecia areata.

Research also suggests that elements of this haplotype may have a protective effect against many autoimmune diseases

Some versions of this haplotype are reported to be protective against Type 1 Diabetes

#### COMMENT:

If biotoxins exposure is suspected, biotoxin load may be reduced through removal from the source of exposure and the use of Cholestryamine. Natural alternatives include calcium bentonite, charcoal, chitosan and chlorella (however may take longer to have the same effect).

If 3 or more of the following factors are present, treatment for CIRS should be undertaken;

- i. VCS Deficitsii. MSH Deficiency
- iv. HLA DQ-DR susceptibility
  v. ADH/Osmolality dysregular
- ii. iii. MMP-9 Elevation
- ADH/Osmolality dysregulation vi. Cortisol/ACTH dysregulation

## FURTHER ASSESSMENTS:

In commencing the treatment process, other baseline assessments include Gliadin and Transglutaminase Antibody levels, anti-Cardiolipin Antibodies, and Androgen studies (DHEAS, SHBG, Testosterone).

Thereafter, specific moulds/biotoxins assays may also be of use. Assays include MSH, ADH,/Osmolality, C3a, C4a, TGFb1, MMP-9 and VEGF.

Page 2 of 3 **Final Report Printed: May 31, 2023** 



P: 1300 688 522 E: info@nutripath.com.au

-.AMY PHILLIPS AIM Natural Healthcare Shop 1/132 WILLOUGHBY ROAD CROWS NEST NSW 2065

# NICOLE PUSIC 13-Dec-1981

4 CENTENNIAL AVENUE LANE COVE NORTH NSW 2066

LAB ID : 3892069 UR NO. : 6191516 Collection Date : 15-May-2023 Received Date: 19-May-2023



3892069

**Female** 

## **Biotoxins Rosetta Stone**

DR RITCHIE SHOEMAKER PROTOCOL HLA-DQDR ROSETTA STONE

DRB1	DQ	DRB3	DRB4	DRB5
4	   3	!!_ 	53	.! 
11/12	3	52B		Ì
14	5	53B		!
7	   2/3	_  -	53	.! 
13	J 6	52A, B, C		1
17	2	52A		1
18*	4	52A		!
15	   6	_  -		.    51
16	J 5	!!!!		51
4	   7/8	_  -	53	.! 
11	   7 			
8	   3,4,6	_  .		.     
7	l   9	I	53	. I . I
12	7	52B		İ
9	j 9	į į	53	į
	11/12 14 7 13 17 18* 15 16 4 11	11/12   3 14   5  7   2/3 13   6 17   2 18*   4  15   6 16   5  4   7/8  11   7  8   3,4,6  7   9 12   7	11/12   3   52B   14   5   53B    7   2/3   13   6   52A, B, C   17   2   52A   18*   4   52A    15   6     16   5   4   7/8    11   7   52B    8   3,4,6    7   9   12   7   52B	11/12   3   52B   7   14   5   53B   7   2/3   53B   5

Reproduced with permission from Dr Ritchie Shoemaker MD.

Tests ordered: IMPEI,CFee,Rosetta,HLADQDR,GOG105